PRTK News and Press, Paratek Pharmaceuticals Inc. From 10/15/21

Today, we revisit Spero Therapeutics for the first time in three years. The company is about to file its first NDA with the FDA by the end of the year. A full investment analysis follows in the paragraphs below. For further details see: Sizing Up Spero Therapeutics

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 PR Newswire WASHINGTON , Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and s...

-- Additional ~$19M Funding for Expanded Anthrax PEP Development Program -- BARDA Contract Now Valued at Up to ~$304M -- Development Milestones Specified for Future Procurements  BOSTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals...

Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +68%, Pieris Pharmaceuticals (NASDAQ:PIRS) +11%, Molecular Templates (NASDAQ:MTEM) +11%, Paratek Pharmaceuticals (NASDAQ:PRTK) +9%, Capricor Therapeutics CAPR +4%. Losers: Kintara Therapeutics KTRA -19%, Oncon...

BOSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA ® (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2021 virtual meeting. Poster presentations will be available...

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, go...

BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...

Image source: The Motley Fool. Paratek Pharmaceuticals (NASDAQ: PRTK) Q2 2021 Earnings Call Aug 09, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Paratek Pharmaceuticals (PRTK) Q2 2021 Earnings Call Transcript

Paratek Pharmaceuticals, Inc. (PRTK) Q2 2021 Earnings Conference Call August 09, 2021 4:30 PM ET Company Participants Paul Arndt – LifeSci Advisors Evan Loh – Chief Executive Officer Adam Woodrow – President and Chief Commercial Officer Randy Brenner – Chief Develo...

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter -- Reported $37.9 Million in Revenue from the Delivery of the First BARDA Procurement of NUZYRA -- Received FDA Ap...